WuXi AppTec Co., Ltd. | TalkMarkets | Page 1
No data available
No data available

Latest Posts

About This Stock More About This Stock
Week In Review: AriBio Sells China Rights To Alzheimer’s Candidate In $770 Million Deal
Article By: ChinaBio® Today
Saturday, March 30, 2024 2:40 PM EDT
South Korea’s AriBio out-licensed China rights for AR1001, an Alzheimer’s disease candidate, in an agreement worth up to $770 million. The company acquiring the asset asked to remain anonymous because of the competition for Alzheimer’s drugs.
In this article: BGNE, AVBP, WUXIF, NUVB Also: SPHDF
Read
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
Article By: ChinaBio® Today
Saturday, March 23, 2024 2:00 PM EDT
Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility.
In this article: MRK, NVO, BGNE, WXXWY, IVBXF, WUXIF Also: NVS, CTLT
Read
Week In Review: Under Pressure From US Congress, WuXi AppTec Resigns From BIO
Article By: ChinaBio® Today
Saturday, March 16, 2024 2:40 PM EDT
BIO, the global lobbying organization for biotechnology firms, forced WuXi AppTec to leave the group due to pressure from the US Congress. Also, Boehringer Ingelheim acquired an option to license drug candidates that treat symptoms of schizophrenia.
In this article: SOLTF, ASLN, REGMF, WUXIF, HNSPF
Read

Latest Tweets for $WUXIF

No tweets yet!

PARTNER HEADLINES